• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Advanced BioHealing

edit

Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft®, for diabetic foot ulcers. Additionally, the Company’s development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with research & development offices in New York, NY and manufacturing operations in La Jolla, CA.

Recent Milestones

edit

• 
  Advanced BioHealing was acquired by Shire. (5/17/11)
  Posted 5/20/11 at 4:37am via yahoo.com
• 
  Advanced BioHealing — Advanced BioHealing plans $200M IPO (5/5/11)
  Posted 5/5/11 at 5:34pm via masshightech.com
• 
  Advanced BioHealing received $25.5M in Series C funding. (2/27/07)
  Posted 3/11/10 at 11:03pm via abh.com
• 
  Advanced BioHealing received $8M in Series B funding. (11/21/05)
  Posted 7/3/10 at 6:03am via abh.com

Videos

Screenshots

edit

Above: Advanced BioHealing
Uploaded: 3/12/10

Sources

1. Shire to buy Advanced BioHealing for $750 million (finance.yahoo.com) [edit]
2. Advanced BioHealing, Inc. Closes $8 Million in First Institutional Financing (abh.com) [edit]
3. Advanced BioHealing Raises $25.5 Million in Series C Financing (abh.com) [edit]
Advanced BioHealing plans $200M IPO (masshightech.com) [edit]